In vitro, in vivo and in silico drugdrug interaction study between Vildagliptin and Bisoprolol fumarate
| dc.contributor.author | Chowdhury, Kazi Ashfak Ahmed | |
| dc.contributor.author | Kabir, Mohammad Shah Hafez | |
| dc.contributor.author | Hossain, Mohammed Munawar | |
| dc.contributor.author | Chowdhury, Tanvir Ahmad | |
| dc.contributor.author | Chakrabarty, Nishan | |
| dc.date.accessioned | 2018-07-31T04:55:01Z | |
| dc.date.available | 2018-07-31T04:55:01Z | |
| dc.date.issued | 2017-06 | |
| dc.description | en_US | |
| dc.description.abstract | Aim of the present study is to evaluate the in vitro, in vivo and in silico drug-drug interaction between Vildagliptin and Bisoprolol fumarate. Interaction between Vildagliptin and Bisoprolol fumarate has been studied in a system of water at a fixed 370C at pH 1.0, 3.0 and 6.8 by using spectral observation, Job’s method of continuous variation, Ardon’s method. In silico complexation was measured by NMR prediction and DDI-CPI analysis. From spectrophotometric study, Vildagliptin and Bisoprolol fumarate give different spectra when Vildagliptin mixed with Bisoprolol fumarate in 1:1 mixture, intensity of spectra of Vildagliptin transform surprisingly due to interaction. The jobs plot was attained by plotting absorbance difference (D) against the mole fraction of the each drug at pH 1, 3, and 6.8. Vildagliptin moderate for 1:1 mixture with Bisoprolol fumarate and slightly lower spectra indicate the formation of 1:1 mixture of Vildagliptin with Bisoprolol fumarate. The value of stability constant for the drug-drug system at pH 1.0, 3.0 and 6.8 are 1.875 0.7778 and 1.2000 respectively. From the IR report it also proved that Vildagliptin and Bisoprolol fumarate produced interaction. In this OGTT test at 1:1, 1:2 and 2:1 complex blood glucose level decrease compared to Vildagliptin. Because when drug-drug interaction happened, then drug cannot exhibit its main activity. That’s why in this test complex showed different activity. In in silico methods, results showed that the drugs interact with each other. So, a careful concern is desired during simultaneous administration of Vildagliptin with Bisoprolol fumarate | en_US |
| dc.identifier.citation | Volume 14, June 2017 Article-3 | en_US |
| dc.identifier.issn | 1813-7733 | |
| dc.identifier.uri | http://dspace.iiuc.ac.bd:8080/xmlui/handle/88203/110 | |
| dc.language.iso | en | en_US |
| dc.publisher | CRP, International Islamic University Chittagong, Bangladesh | en_US |
| dc.subject | Drug-drug interaction | en_US |
| dc.subject | Vildagliptin | en_US |
| dc.subject | Bisoprolol fumarate | en_US |
| dc.subject | Ardon’s | en_US |
| dc.subject | Jobs method | en_US |
| dc.subject | OGTT | en_US |
| dc.title | In vitro, in vivo and in silico drugdrug interaction study between Vildagliptin and Bisoprolol fumarate | en_US |
| dc.type | Article | en_US |